Introduction
============

The multi-resistance gene *cfr* encodes a methyltransferase that modifies position A2503 at 23S rRNA and confers resistance to six different classes of antibiotics that bind to the peptidyl transferase center ([@B14]; [@B12]). Cfr confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics (the PhLOPS~A~ phenotype) and reduces susceptibility to the 16-membered macrolides josamysin and spiramycin ([@B18]), which are used extensively in the treatment of infections in both humans and animals. Oxazolidinones, in particular, are regarded as the last defense against methicillin-resistant *Staphylococcus aureus* (MRSA) or vancomycin-resistant enterococci in humans ([@B27]). The *cfr* gene was first identified in a bovine *Staphylococcus sciuri* isolate ([@B25]) and subsequently in staphylococcal isolates of human and animal origin from around the world ([@B23]). In addition, various *Enterococcus*, *Bacillus*, *Macrococcus*, *Jeotgalicoccus*, *Streptococcus suis*, *Proteus vulgaris*, and *Escherichia coli* strains have also been reported to be *cfr*-positive ([@B23]; [@B32]). The *cfr* gene is not only widely disseminated in staphylococci from pigs in China ([@B23]), but also increasingly reported in porcine *E. coli* isolates in China. To date, a total of 16 *cfr*-positive *E. coli* isolates have been identified in the Shandong, Sichuan, Guangxi, and Guangdong provinces, China ([@B9]; [@B31]; [@B40]; [@B38]; [@B39]), suggesting the possibility of the transfer of *cfr* from *Staphylococcus* to *E. coli*. In this study, we identified *cfr*-positive *Staphylococcus* spp. and *E. coli* isolates from the same farm and determined the complete nucleotide sequence of a novel conjugative F43:A-:B- plasmid bearing *cfr* in an *E. coli* isolate.

Materials and Methods {#s1}
=====================

Sampling and Bacterial Isolates
-------------------------------

A total of 323 pig nasal swab samples and 442 fecal samples were collected in 2013 from six swine farms located in four geographically distinct provinces in China: one farm in Jilin (DBNA), two farms in Guangdong (GDEP and GDYD), one farm in Jiangxi (JXTC), and two farms in Henan (HNYM and HNYC). The usage of antibiotic agents at these farms over the past year (except farm DBNA) was supplied by their veterinarians. All animal studies were performed with the approval of the Animal Care and Use Committee of South China Agriculture University. Nasal swab samples were incubated in 7.5% Sodium Chloride Broth for 16--18 h at 37°C and then streaked onto Mannitol Salt agar plates and grown for 16--18 h at 37°C. Next, one presumptive staphylococcal isolate per sample was randomly selected for further analysis. Fecal samples were used to isolate *E. coli* as previously described ([@B4]). Species identification of all *cfr*-positive strains was determined by the ID32 STAPH system (bioMérieux, Craponne, France) and was further confirmed by sequencing the 16S rRNA using universal prokaryotic primers ([@B34]).

Identification of Resistance Genes and the Genetic Environment of *cfr*
-----------------------------------------------------------------------

All *Staphylococcus* spp. and *E. coli* isolates were screened for the presence of *cfr* by polymerase chain reaction (PCR) as previously described ([@B13]). The *cfr*-positive staphylococci were also PCR-screened for the presence of the *fexA*, *fexB*, *mecA*, and *mecC* genes ([@B19]; [@B13]; [@B16]; [@B21]). Additionally, the *cfr*-positive *E. coli* strains were screened for *floR* ([@B5]).

The genetic context surrounding *cfr* was examined by PCR mapping and sequencing in eight randomly selected *cfr*-positive *Staphylococcus* spp. and two *cfr*-positive *E. coli* isolates. The primers used to determine the regions upstream and downstream of *cfr* are listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

Antimicrobial Susceptibility Testing
------------------------------------

All *cfr-*positive *Staphylococcus* spp. and *E. coli* isolates were tested for their antimicrobial susceptibility using the agar dilution method. Antimicrobial susceptibility tests were conducted and evaluated according to the recommendations specified in CLSI documents VET01-S2 ([@B6]) and M100-S25 ([@B7]). Minimal inhibitory concentrations (MICs) of ≥16 mg/L were tentatively considered as criteria of florfenicol resistance ([@B13]). *S. aureus* ATCC^®^29213 and *E. coli* ATCC^®^25922 served as quality control strains.

Multilocus Sequence Typing (MLST)
---------------------------------

Seven housekeeping genes, including *adk, fumC, gyrB, icd, mdh, purA*, and *recA*, were used to determine the sequence types (STs) of all the *cfr*-positive *E. coli* ([@B15]). The MLST databases were used for BLAST analysis^[1](#fn01){ref-type="fn"}^.

Pulsed-Field Gel Electrophoresis (PFGE)
---------------------------------------

Pulsed-field gel electrophoresis (PFGE) was used to determine the clonality of the *cfr*-positive *S. sciuri* isolates. Whole-cells were packed with an equal volume of 2% (wt/vol) low melting point agarose (Bio-Rad, Laboratories, Hercules, CA, USA) dissolved in EC buffer ([@B17]) and poured into plug molds. The frozen plugs were addressed according to the previously described with minor modification. The digested fragments were separated using a CHEF-DRIII system (Bio-Rad) with a clamped homogeneous electric field of 6 V/cm, using a 120° switch angle for 24 h at 14°C, with the pulse time linearly ramped from 3 to 40 s. PFGE was performed for all *cfr*-positive *E. coli* isolates using the CHEF Mapper System (Bio-Rad), according to a previously described protocol ([@B4]). Comparison of PFGE patterns was performed using the BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium) using the Dice coefficient (1.5% optimization and 1.0% tolerance); a similarity cutoff of 80% was used to identify a PFGE cluster.

S1-Pfge, Conjugation/Transformation, and Replicon Type of *cfr*-Carrying Plasmids from *E. coli*
================================================================================================

S1 nuclease pulsed-field gel electrophoresis (S1-PFGE) combined with Southern blotting was performed to determine the location of *cfr* in *E. coli* and the size of the plasmid according to previous protocol with minor modifications ([@B2]). Conjugation experiments were conducted using *E. coli* C600 (streptomycin resistant) as the recipient. Transconjugants were selected on MacConkey agar containing 3000 mg/L streptomycin and 10 mg/L florfenicol. Plasmid DNA was extracted from *cfr-*carrying *E. coli* strains and transformed into *E. coli* recipient strain DH5α (Takara) using the calcium chloride method when the *cfr*-carrying plasmid could not be transferred to *E. coli* C600 via conjugation. Transformants were selected on Luria-Bertani agar plates containing 10 mg/L florfenicol. The replicon types of *cfr*-carrying plasmids were determined by PCR-based replicon typing (PBRT), as previously described ([@B3]). Replicon sequence typing (RST) was performed to further characterize the IncFII plasmid ([@B28]).

Sequencing of Plasmid pHNEP28
-----------------------------

Plasmid pHNEP28 from porcine *E. coli* isolate EP28 was purified from a transconjugant using a Qiagen plasmid midi kit (Qiagen, Hilden, Germany) and 3 μg DNA was quantified by NanoDrop^TM^ 2000/2000c Spectrophotometers from Thermo Scientific. Sequence was performed by the Roche 454 GS-FLX system. Contigs were assembled with the 454 GS de novo assembler (Newbler) v2.8. Gaps between contigs were closed by PCR and sequencing. Annotation of pHNEP28 was performed using the RAST server ([@B1]), ISfinder^[2](#fn02){ref-type="fn"}^, and BLAST^[3](#fn03){ref-type="fn"}^.

Statistical Analysis
--------------------

Statistical significance for the comparison of prevalence data was determined by the *x*^2^-test. *p-*values less than 0.05 were regarded as statistically significant.

Nucleotide Sequence Accession Number
------------------------------------

The nucleotide sequence of the plasmid pHNEP28 has been deposited with the GenBank nucleotide sequence database under accession number [KT845955](KT845955).

Results
=======

Detection of *cfr* and Antimicrobial Susceptibility of *cfr*-Positive Isolates
------------------------------------------------------------------------------

Two-hundred and fifty four *Staphylococcus* spp. strains and 398 *E. coli* strains were recovered from the 323 nasal swab and 442 fecal samples, respectively (**Table [1](#T1){ref-type="table"}**). Among them, *cfr* was detected in 40 (15.7%) *Staphylococcus* spp. and two (0.5%) *E. coli* isolates. Farm GDEP in the Guangdong province showed the highest prevalence of *cfr*-positive (37.5%) *Staphylococcus* spp. strains and it was also the only farm with *cfr*-positive *E. coli* strains (**Table [1](#T1){ref-type="table"}**). The predominant *cfr*-positive *Staphylococcus* spp. species was *S. sciuri* (*n* = 38); additionally, one *S. chromogenes* isolate was obtained from farm HNYC and one *S. lentus* isolate was found at farm GDYD.

###### 

Detection rates of *cfr* and *fexA* among 40 *Staphylococcus* spp. and 2 *Escherichia coli* strains from six pig farm.

          *Staphylococcus* spp.^1^   *E. coli*   Drugs used in these farms                                              
  ------- -------------------------- ----------- --------------------------- ---- ----- ---- ---- ----- ----- --------- --------------------------------------
  DBNA    70                         46          8 (17.4)                    4    15    4    2    30    26    0         n.a.
  GDEP    24                         24          9 (37.5)                    9    18    9    9    48    41    2 (4.9)   AMC,KAN,GEN,PEN,LIN,AMP, ENO,STR,FLR
  GDYD    29                         20          7 (35)                      7    11    4    4    49    39    0         FLR
  JXTC    50                         47          12 (25.5)                   10   31    5    5    119   105   0         CEF,TET,FLR,TIL,LIN,TYL,AMC
  HNYM    50                         48          0 (0)                       0    20    0    0    99    94    0         GEN,PEN,ENO,CEF,TUL
  HNYC    100                        69          4 (5.8)                     2    52    4    2    97    93    0         GEN,PEN,ENO,CEF,TUL
  Total   323                        254         40 (15.7)                   32   147   26   22   442   398   2 (0.5)   

AMC, amoxicillin; CEF, cefotaxime; KAN, kanamycin; GEN, gentamicin; PEN, penicillin; LIN, lincomycin; AMP, ampicillin; ENO, enrofloxacin; STR, streptomycin; TET, tetracycline; FLR, florfenicol; TIL, tilmicosin; TYL, Acetylisovaleryltylosin Tartrate; TUL, tulathromycin; n.a., not available.
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38 Staphylococcus sciuri, 1 Staphylococcus lentus and 1 Staphylococcus chromogenes.

Antimicrobial Resistance and Resistance Determinants
----------------------------------------------------

Antimicrobial susceptibility assays showed that all 40 *cfr*-positive *Staphylococcus* spp. isolates exhibited resistance to erythromycin, tetracycline, clindamycin, and trimethoprim-sulfamethoxazole. In addition, 39 (97.5%), 37 (92.5%), 36 (90%), 36 (90%), and 34 (85%) *cfr*-positive *Staphylococcus* spp. isolates demonstrated resistance to oxacillin, tiamulin, valnemulin, florfenicol, and gentamicin, respectively. Of the 40 *cfr*-positive staphylococci, 19 (47.5%) and 11 (27.5%) were resistant to ciprofloxacin and rifamycin, while only three (7.5%) isolates were linezolid-resistant (**Table [2](#T2){ref-type="table"}** and Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). The two *cfr*-positive *E. coli* strains also exhibited a multiresistance phenotype, namely, ampicillin, tetracycline, streptomycin, florfenicol, and trimethoprim-sulfamethoxazole resistance. Strain EP28 was also ciprofloxacin-resistant (**Table [3](#T3){ref-type="table"}**).

###### 

Characteristics of 40 *cfr*-carrying *Staphylococcal* spp. isolates.

                                                                                                 Genotype characterization        
  --------- ---- ------------------ ------------------------------------------------------------ --------------------------- ---- -----------------------------------------
  JXTC3     A1   *S. sciuri*        TIA,VAL,OX,GEN,CIP,SXT,EM,TET,CLI                            \+                               
  JXTC7     C    *S. sciuri*        FLR,TIA,VAL,OX,FOX, CIP,SXT,EM,TET,CLI                       \+                               
  JXTC8     D    *S. sciuri*        FLR, TIA,VAL,OX,FOX,GEN, CIP,SXT,EM,TET,CLI                  \+                               
  JXTC9     A2   *S. sciuri*        FLR, TIA,VAL,OX,GEN, CIP,SXT,EM,TET,CLI                      \+                               
  JXTC11    B1   *S. sciuri*        FLR, TIA,VAL,OX,GEN, RIF, CIP,SXT,EM,TET,CLI                 \+                               
  JXTC13    A3   *S. sciuri*        FLR, TIA,VAL,PEN,AMP,OX,FOX,GEN,SXT,EM, TET,CLI              \+                               
  JXTC17    B2   *S. sciuri*        FLR, TIA,VAL,OX, FOX,GEN,CIP,SXT,EM,TET,CLI                  \+                          \+   
  JXTC28    E    *S. sciuri*        FLR, TIA,VAL,AMP,OX,GEN, CIP,SXT,EM,TET,CLI                                              \+   ΔIS*1216-aacA-aphD-*IS*256-cfr-*IS*256*
  JXTC29    F    *S. sciuri*        FLR, TIA,VAL,LNZ, OX, GEN, RIF,CIP,SXT,EM, TET,CLI           \+                          \+   
  JXTC30    G    *S. sciuri*        FLR, TIA,VAL,LNZ,AMP,OX,FOX,GEN,SXT,EM, TET,CLI                                          \+   
  JXTC31    H    *S. sciuri*        FLR,TIA,VAL,OX, RIF, CIP,SXT,EM,TET,CLI                      \+                          \+   
  JXTC40    I    *S. sciuri*        FLR, TIA,VAL,OX,GEN, CIP,SXT,EM,TET,CLI                      \+                               
  GDYD26    J    *S. sciuri*        FLR, TIA,VAL,OX,FOX,GEN,SXT,EM,TET,CLI                       \+                          \+   IS*21-558-cfr-*Δ*tnpB*
  GDYD27    K    *S. sciuri*        FLR, TIA,OX,GEN,SXT,EM,TET,CLI                               \+                               
  GDYD28         *S. lentus*        FLR, TIA,VAL,OX,GEN,SXT,EM,TET,CLI                           \+                          \+   
  GDYD35    L    *S. sciuri*        FLR, VAL, OX,FOX,SXT,EM,TET,CLI                              \+                          \+   
  GDYD36    M    *S. sciuri*        FLR, TIA,VAL,OX,FOX,GEN,SXT,EM,TET,CLI                       \+                          \+   
  GDYD38    N    *S. sciuri*        FLR, TIA,VAL,OX,FOX,GEN,SXT,EM,TET,CLI                       \+                               
  GDYD39    O    *S. sciuri*        FLR, TIA,VAL,OX,FOX,GEN,SXT,EM,TET,CLI                       \+                          \+   
  GDEP17    P    *S. sciuri*        FLR, VAL,OX,SXT,EM,TET,CLI                                   \+                          \+   
  GDEP24    Q    *S. sciuri*        FLR, TIA,VAL,OX,FOX,GEN,SXT,EM,TET,CLI                       \+                          \+   IS*21-558-cfr-*Δ*tnpB*
  GDEP26    R    *S. sciuri*        FLR,TIA,VAL,OX,FOX,GEN,SXT,EM,TET,CLI                        \+                          \+   
  GDEP27    S    *S. sciuri*        FLR,TIA,VAL, OX,GEN, CIP,SXT,EM,TET,CLI                      \+                          \+   IS*Enfa4-cfr-* IS*Enfa4*
  GDEP39    T    *S. sciuri*        FLR,TIA,VAL,OX,GEN,SXT,EM,TET,CLI                            \+                          \+   IS*21-558-cfr-*Δ*tnpB*
  GDEP40    U    *S. sciuri*        FLR,TIA,VAL,OX,FOX,GEN,SXT,EM,TET,CLI                        \+                          \+   
  GDEP43    V    *S. sciuri*        FLR,TIA,VAL,OX,GEN,SXT,EM,TET,CLI                            \+                          \+   IS*21-558-cfr-*Δ*tnpB*
  GDEP44    W    *S. sciuri*        FLR,TIA,VAL,OX,GEN,SXT,EM,TET,CLI                            \+                          \+   
  GDEP48    X    *S. sciuri*        FLR, TIA,VAL,OX,FOX,GEN,SXT,EM,TET,CLI                       \+                          \+   
  HNYC8          *S. chromogenes*   FLR, TIA,VAL,TET, RIF,SXT,EM,TET,CLI                                                     \+   
  HNYC31         *S. sciuri*        FLR, TIA,VAL,PEN,AMP,OX,FOX,GEN,SXT,EM, TET,CLI              \+                          \+   
  HNYC32    Y    *S. sciuri*        TIA,VAL,OX,GEN, RIF,SXT,EM,TET,CLI                                                       \+   
  HNYC49    Z    *S. sciuri*        FLR,TIA,VAL,LNZ RIF,PEN,AMP,OX,FOX,GEN, CIP,SXT,EM,TET,CLI   \+                          \+   
  DBNA9-2   AA   *S. sciuri*        FLR,TIA,VAL,OX,GEN, RIF,CIP,SXT,EM,TET,CLI                                                    
  DBNA12         *S. sciuri*        FLR,TIA,OX,GEN,RIF,CIP,SXT,EM,TET,CLI                        \+                          \+   IS*21-558-cfr-*Δ*tnpB*
  DBNA15         *S. sciuri*        FLR,TIA,VAL,OX,FOX,GEN,RIF,CIP,SXT,EM,TET,CLI                \+                          \+   
  DBNA16         *S. sciuri*        FLR,TIA,VAL,OX,GEN,RIF,CIP,SXT,EM,TET,CLI                                                \+   
  DBNA21         *S. sciuri*        FLR,TIA,VAL,OX,FOX,GEN,RIF,CIP,SXT,EM,TET,CLI                                                 
  DBNA22         *S. sciuri*        OX,RIF,SXT,EM,TET,CLI                                        \+                               
  DBNA23         *S. sciuri*        FLR,TIA,VAL,RIF,OX,GEN,CIP,SXT,EM,TET,CLI                    \+                          \+   
  DBNA47    AB   *S. sciuri*        FLR,TIA,VAL, OX,GEN,SXT,EM,TET,CLI                                                            IS*21-558-cfr-*Δ*tnpB*

PEN, penicillin; OX, oxacillin; FOX, cefoxitin; AMP, ampicillin; CIP, ciprofloxacin; TIA, tiamulin; SXT, trimethoprim-sulfamethoxazole; LNZ, linezolid; VAL, valnemulin; VAN, vancomycin; CLI, clindamycin; GEN, gentamycin; EM, erythromycin; RIF, rifamycin; TET, tetracycline; FLR, florfenicol; ND, not determined.
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For eight randomly selected S. sciuri isolates.

Of the 40 *cfr*-positive staphylococcal isolates, 25 strains carried *fexA*, while *fexB* was not detected. Interestingly, 32 of the 39 oxacillin-resistant staphylococci harbored *mecA*; *mecC* was not detected in the remaining seven *mecA*-negative strains. In addition, *mecA*, *fexA*, and *cfr* coexisted in 22 staphylococci (**Table [2](#T2){ref-type="table"}**). The *cfr*-positive *E. coli* strain EP28 also carried *floR* (**Table [3](#T3){ref-type="table"}**).

###### 

Characteristics of 2 *cfr*-carrying *E. coli* isolates and their transconjugant/transformant.

  Isolates^1^   Resistance Phenotype (mg/mL)   MLST    PFGE   Genotype characterization                                                        
  ------------- ------------------------------ ------- ------ --------------------------- ----- ------- ------ ------ ------- ------ ---- ---- -------------------------------------------------
  EP28          ≥32                            0.125   2      128                         1     256     \>64   \>64   4       4241   A'   \+   IS*26*-*cfr*-IS*26* in the same orientation
  EP25          ≥32                            0.125   2      128                         0.5   \>256   \>64   \>64   0.5     1602   B'        IS*26*-*cfr*-IS*26* in the opposite orientation
  C600          2                              0.015   2      1                           0.5   \>256   0.25   2      0.008                    
  EP28-2J       ≥32                            0.125   2      2                           0.5   \>256   0.25   \>64   0.5                 \+   IS*26*-*cfr*-IS*26* in the same orientation
  DH5α          4                              0.03    1      2                           0.5   4       0.5    4      0.008                    
  EP25-1Z       ≥32                            0.125   1      32                          0.5   \>256   32     \>64   0.06                     IS*26*-*cfr*-IS*26* in the opposite orientation

AMP, ampicillin; CTX, cefotaxime; AMI, Amikacin; TET, tetracycline; GEN, gentamycin; STR, streptomycin; SXT, trimethoprim-sulfamethoxazole; FLR, florfenicol; CIP, ciprofloxacin.

1

EP28 and EP25 are original cfr-positive isolates; C600 is transconjugant receptor; EP28-2J is transconjugan from isolate EP28; DH5α is transformant receptor; EP25-1Z is transformant from EP25.

Molecular Typing
----------------

The 38 *cfr*-positive *S. sciuri* strains were analyzed by PFGE and 28 major *Sma*I patterns were observed, whereas seven strains were nontypeable by PFGE using *Sma*I (**Table [2](#T2){ref-type="table"}** and Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). Although obtained from the same farm, the two *cfr*-carrying *E. coli* isolates were not related (**Table [3](#T3){ref-type="table"}**). The *cfr*-positive *E. coli* strain EP25 was shown to belong to ST1602, whereas *E. coli* EP28 represented a novel ST, ST4241 (**Table [3](#T3){ref-type="table"}**). Interestingly, five *cfr*-positive *S. sciuri* strains isolated from the same farm located in the Jiangxi province were grouped in two clusters (Dice similarity index was ≥80%): strains with similar PFGE patterns A1, A2, and A3, and two strains showing related PFGE patterns B1 and B2.

Genetic Environment of *cfr*
----------------------------

The regions surrounding *cfr* were determined by PCR mapping and sequencing in eight randomly selected *Staphylococcus* strains. In six isolates, IS*21-558* was identified 99% identity with upstream of *cfr* and truncated transposase gene *tnpB* was found downstream of *cfr* (**Table [2](#T2){ref-type="table"}**). This arrangement (IS*21-558-cfr-*Δ*tnpB*) is identical 99% identity to the corresponding region of plasmids pSS-02 (accession no. JF834910, *S. saprophyticus*, swine, China), pHNTLD18 (accession no. KF751702, *S. equorum*, pork, China), pSA737 (accession no. KC206006, *S. aureus*, patient, USA), pHK01 (accession no. KC820816, *S. cohnii*, patient, China), and pHNCR35 (accession no. KF861983, *S. simulans*, hog market worker, China) ([@B29]).

In *S. sciuri* strain GDEP27, *cfr* was bracketed by two copies of IS*Enfa4* in the same orientation, which was identical 98% identity to the corresponding region of *E. faecalis* pW9-2 (accession no. JQ911741, sewage at pig farm, China) and pHOU-*cfr* (accession no. JQ660368, patient, Thailand), *E. thailandicus* pW3 (accession no. JQ911739, sewage at pig farm, China), and p3-38 (accession no. JQ911740, pig, China).

In *S. sciuri* strain JXTC28, *cfr* is bracketed by two copies of IS*256* in the same orientation, a partial fragment of IS*1216* and the aminoglycoside resistance gene *aacA*-*aphD* were located downstream of IS*256*. This ΔIS*1216-aacA-aphD-*IS*256-cfr-*IS*256* module was 98% identity to that found on plasmid pSS-04 (accession no. KF129410) carried by porcine *S. sciuri* GN5-1 in Sichuan province, China.

In both *cfr*-positive *E. coli* strains, the *cfr* gene was flanked by two copies of IS*26* (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}). Strain EP25 had a similar genetic environment to plasmids pEC-01 (accession no. JN982327) identified in a porcine *E. coli* strain from the Shandong province, China, and pSD7 (accession no. KJ453116) found in a porcine *E. coli* isolate from the Guangdong province, China; 2 copies of IS*26* located in the same orientation, but opposite to *cfr* gene (Supplementary Figure [S2B](#SM1){ref-type="supplementary-material"}). In EP28, the 2 copies of IS*26* are in opposite orientation relative to one another, with *cfr* in the same orientation than IS*26* right-copy (Supplementary Figure [S2A](#SM1){ref-type="supplementary-material"}).

Transformation of Plasmids Carrying *cfr* into *E. coli*
--------------------------------------------------------

S1-PFGE and Southern blotting showed that the *cfr* gene in isolates EP25 and EP28 were located on a plasmid of approximately 95 and 105 kb, respectively. The *cfr*-carrying plasmids from isolate EP28 and EP25, designated as pHNEP28 and pHNEP25, were successfully transferred to *E. coli* C600 and DH5α, respectively. Plasmid pHNEP28 was identified as F43:A-:B-, while the replicon type of pHNEP25 could not be determined using the PBRT method. Both the transconjugant EP28-2J and the transformant EP25-1Z exhibited resistance against ampicillin, florfenicol, and elevated MICs of cefotaxime and ciprofloxacin, compared with the recipient *E. coli* strain (C600 or DH5α; **Table [3](#T3){ref-type="table"}**). In addition, EP25-1Z also showed resistance to tetracycline, streptomycin, and sulfamethoxazole-trimethoprim, whereas the acquisition of pHNEP28 increased tetracycline MIC by only onefold.

Characterization of pHNEP28 from *E. coli* Strain EP28
------------------------------------------------------

Sequence analysis revealed that pHNEP28 is 108,837 bp in size with an average GC content of 49.85% (contigN50: 108837 bp). Plasmid pHNEP28 consisted a typical IncFII-type backbone (83,398 bp) encoding plasmid replication, horizontal transfer, maintenance and stability functions, and two multi-resistance regions (MRR) (**Figure [1](#F1){ref-type="fig"}**).

![**Circular map of the IncFII:43 plasmid pHNEP28.** The most external circle represents the size of complete plasmid circle in bp. The clockwise orientation open reading frames (ORFs) are presented first and then in the counterclockwise orientation. The inner circle indicates the functional regions. The G+C plot is displayed in the inner circle, with yellow indicating \>50% and purple indicating \<50%.](fmicb-08-00329-g001){#F1}

The replication region (position 36,852--38,269 bp), consisting of *repA2* and *repA1*, was classified as F43:A-:B:- by RST. This region shared 97% identity to two F2:A-:B- NDM-producing plasmids from *E. coli* isolates: pMC-NDM (accession no. HG003695) and pGUE-NDM (accession no. JQ364967). The transfer-leading region comprised genes related to plasmid maintenance and stability, including *parA*, *parB*, and *ssb*, as well as many putative genes. Additionally, genes involved in induced mutagenesis and DNA damage tolerance (*umuC* and *umuD*) and in the inhibition of the bacterial SOS response (*psiA* and *psiB*) were also identified. A section of the plasmid transfer-leading region (position 4,906--15,340 bp) shared 99% nucleotide identity with *Enterobacter cloacae* plasmid pIMP-HB623 (accession no. KM877517). Another section (position 77,101--88,852 bp) showed 97% identity to enteropathogenic *E. coli* plasmid p026_2 (accession no. AP010955).

The transfer region of pHNEP28 included 24 *tra* genes and *finO* and is less highly related to other IncFII plasmids, with ∼94%-97% identity to this region in *E. coli* plasmid pEB3 (accession no. CP006001) from Vietnam, which was designed to F30:A-:B:- by RST. Furthermore, the partial *tra* region of pHNEP28 (position 69475-77025 bp) showed high homology (98% nucleotide identity) with plasmids pMC-NDM and pGUE-NDM.

The pHNEP28 contained two mosaic MRR regions (**Figure [2](#F2){ref-type="fig"}**). The first 9,677 bp MRR, located downstream of the replication region, contains two resistance genes (*tet*(M) and *bla*~TEM-1~) and complete or truncated insertion sequences and transposons (IS*1B*, Δ*intI4*, ΔTn2, IS*AplI*, and IS*26*). The *tet*(M) gene found in pHNEP28 shared 96--98% nucleotide identity with sequences in *S. pneumoniae* strain 11930 (accession no. FR671416), Tn*916*-like transposon Tn*6085* from *E. faecium* (accession no. HM243623), Tn*916*/Tn*1545*-like transposon from *E. faecalis* (accession no. DQ223241), and *S. aureus* strain TW20 (accession no. NG_048252); whereas it was identical to the *tet*(M) gene from porcine *E. coli* isolate CICYT-332 (accession no. KJ755873) found in Spain, although only 1802/1935 bps of CICYT-332 *tet*(M) were sequenced. While *tet*(M) demonstrated only 96% identity to that in plasmid pTCY4 (KJ772289, duck *E. coli*, China), the 1,204-bp module (IS*26*-*orf12*-*orf13*) upstream of *tet*(M) was identical to the corresponding region of pTCY4. Transposon Tn*2* carrying resistance gene *bla*~TEM-1~ was interrupted by IS*Apl1*, which generated 2-bp direct repeats (DR) (5′-CT-3′); *tnpR* of Tn*2* was truncated by IS*26*, which interrupted another Tn*2* with an opposite orientation (**Figure [2A](#F2){ref-type="fig"}**).

![**Multiresistance regions in plasmid pHNEP28.** The arrows indicate the positions and transcription directions of the genes. Regions with \>99% homology are shaded in gray. Δ indicates a truncated gene. Black circles mean direct repeats generated by the insertion of IS*Apl1*. **(A)** Multiresistance region I in plasmid pHNEP28 **(B)** Mutiresistance region II in plasmid pHNEP28 and the structural comparison with other plasmids.](fmicb-08-00329-g002){#F2}

Another MRR module (14,370 bp), including the multiresistance gene *cfr*, florfenicol efflux pump gene *floR*, and quinolone resistance gene *qnrS1*, was inserted into the plasmid stability region. As shown in **Figure [2B](#F2){ref-type="fig"}**, the *cfr* gene was flanked by two IS*26* located in the opposite orientation, in agreement with the result obtained by PCR mapping. In addition, the 2,513-bp module (Δ*rep*-IS*26*) was identical to the corresponding region in plasmids pHNFP671 (accession no. KP324830), pSD6 (accession no. KJ453115), and pFSEC-01 (accession no. KR779901) from porcine *E. coli* in China. In plasmid pHNEP28, the Δ*rep*-IS*26* region was found in the opposite orientation with a second copy of IS*26* present in the downstream region. Furthermore, another IS*26* element is present downstream of *cfr* on plasmids pHNFP671 and pSD6, though the 2,414-bp segment containing *cfr* and IS*26* was identical to plasmid pHNEP28 in our study (**Figure [2B](#F2){ref-type="fig"}**).

Moreover, plasmid-mediated quinolone resistance gene *qnrS1* was flanked by two copies of IS*Kpn19* located in the opposite orientation, although the first one was interrupted by IS*26* (**Figure [2B](#F2){ref-type="fig"}**). The 4615-bp module (*qnrS1-*IS*Kpn19*) was present in multiple plasmids, such as *Klebsiella pneumoniae* plasmids pNDM-1fa (CP014757, human, USA) and pK1HV (HF545434, human, Vietnam), and *E. coli* plasmids pPGRT46 (KM023153, human, Nigeria), pEQ2 (KF362122, equine, Czech Republic), and pKT58A (JX065631, water fowl, Slovakia) ([@B10]). The IS*26*-ΔIS*Kpn19*-Δ*qnrS1* module was identical 99% to that in *E. coli* isolate E80 (KF921555, raw wastewater, Portugal), containing a disrupted *qnrS1* gene (**Figure [2B](#F2){ref-type="fig"}**). The 4,292-bp segment (Δ*virD2*-*floR*-ΔIS*CR2*) was identical 99% identity to the corresponding region of plasmids pHNSHP45-2 (KU34138, porcine *E. coli*, China), pHXY0908 (KM877269, chicken *Salmonella* Typhimurium, China), and pK1HV (HF545434, human *K. pneumoniae*, Vietnam); however, both *virD2* and IS*CR2* were truncated by IS*26* in plasmid pHNEP28 (**Figure [2B](#F2){ref-type="fig"}**).

Discussion
==========

In this study, *cfr* was identified in 15.7 and 0.5% of *Staphylococcus* spp. and *E. coli* isolates from pigs, respectively. The prevalence of *cfr* among *E. coli* strains was still low, which is in agreement with a previous report ([@B9]). However, to the best of our knowledge, this is the first report of *cfr* being found in *Staphylococcus* spp. and *E. coli* strains at the same farm. The presence of *cfr*-positive *E. coli* at farm GDEP may not be surprising given the high prevalence of *cfr*-positive staphylococci at that farm. The prevalence of *cfr*-positive staphylococci from farms GDEP (37.5%) and GDYD (35.5%) in the Guangdong province and from farm JXTC (25.5%) in the Jiangxi province was significantly higher than that in strains from farms HNYM (0%) and HNYC (5.8%) located in the Henan province (*p* \< 0.5). According to drug usage records, florfenicol is used prophylactically or for treatment of bacterial diseases at farms GDEP, GDYD, and JXTC, but not at farms HNYM and HNYC (**Table [1](#T1){ref-type="table"}**), which may account for the different detection rates. The direct selective pressure imposed by florfenicol appears to be the main driving force promoting the dissemination of *cfr* among same or different species at the same farm. This hypothesis is further supported by the presence of the florfenicol efflux gene *floR* in one *cfr*-positive *E. coli* isolate and the florfenicol efflux gene *fexA* in 25 *cfr*-carrying staphylococcal strains, which is higher than the prevalence of *fexA* among *cfr*-positive staphylococci (17/33, 51.5%) obtained from pigs in the Shandong province, China in 2011 ([@B33]). In addition, the *cfr*-carrying isolates may also persist and be co-selected under the pressure of other agents; the results of the antimicrobial susceptibility assay reveal that the *cfr*-positive staphylococci exhibit a multiresistance phenotype, which is not limited to PhLOPS~A~.

In the present study, *S. sciuri* (*n* = 38) was the predominant species among the 40 *cfr*-positive staphylococcal strains. Previous report indicates that *S. sciuri* might be a reservoir for resistance and virulence genes both in veterinary and human medicine ([@B20]). *cfr* was first identified on plasmid pSCFS1 from a bovine *S. sciuri* in Germany ([@B25]) and has since been detected on plasmids or the chromosomal DNA in *S. sciuri* strains from pigs and cattle in Germany ([@B13]) and from pigs, duck, chickens, and chicken meat in China ([@B31], [@B30]; [@B37]), indicating that *S. sciuri* is an important reservoir for the *cfr* gene, which contributes to the spread of *cfr* among animals and animal food. *Sma*I PFGE performed to further elucidate the dissemination of *cfr*-positive *S. sciuri*, revealed a variety of patterns. Most of the *cfr*-carrying *S. sciuri* isolates were clonally unrelated, indicating that the spread of *cfr* in pig farms was not due to clonal dissemination. The related PFGE patterns exhibited by a number of strains from farm JXTC, suggest that clonal dissemination of *cfr*-positive *S. sciuri* had occurred at this farm. However, the main mechanism for the dissemination of *cfr* among *S. sciuri* was probably horizontal transmission mediated by mobile genetic elements. The presence of a similar *cfr*-harboring module (IS*21-558-cfr-*Δ*tnpB*) in six randomly selected *S. sciuri*, which was identical to corresponding regions of plasmids from animals, humans, and food, may further confirm this hypothesis. In addition, *cfr* was bracketed by two copies of IS*Enfa4* or IS*256* in *S. sciuri* strain GDEP27 and JXTC28, respectively, which was highly similar to that in *Enterococcus* or *Staphylococcus* isolates, further suggesting these insertion sequences are associated with the transmission of *cfr* among same or different species from various sources.

Similarly, the two *cfr*-carrying *E. coli* showed different *Xba*I PFGE patterns and ST types. Additionally, *cfr* was flanked by two copies of IS*26* in both strains, as previously reported in other *E. coli* plasmids, whereas IS*26* in strain EP28 was in the opposite orientation. IS*26* is widespread among gram-negative bacteria and can mediate the mobility of *cfr* in gram-negative isolates ([@B23]). The *cfr*-harboring module (IS*26*-*cfr*-IS*26*) was the most prevalent genetic structure among *E. coli* strains, though *cfr* was flanked by two copies of IS*256* on plasmid pSCEC2, identified in an *E. coli* isolate ([@B40]). IS*26* may play an important role in the dissemination of *cfr*, in accordance with previous reports ([@B9]; [@B38]).

Plasmid pHNEP28 obtained in the present study from *E. coli* isolate EP28 was classified as F43:A-:B- by RST. Because *cfr* has not been detected previously in an IncFII plasmid, plasmid pHNEP28 was fully sequenced. In addition to the multiresistance gene *cfr*, pHNEP28 contains four other resistance genes including *tet*(M), *bla*~TEM-1~, *floR*, and *qnrS1*. Similar to *cfr*, *tet*(M) is widely disseminated among various gram-positive organisms and is commonly related to transposons Tn*916* and Tn*1545* ([@B24]; [@B36]; [@B22]). Although *tet*(M) found in pHNEP28 showed only 96--98% identity to that from gram-positive isolates and only a slightly increased (onefold) tetracycline MIC, it was identical to the *tet*(M) identified in porcine *E. coli* isolate CICYT-332 from Spain, which was classified as a new *E. coli tet*(M) allele distantly related to enterococcal *tet*(M) sequences based on phylogenetic analysis; thus, the possibility of gram-positive to gram-negative strain transfer of *tet*(M) cannot be ruled out. Additionally, the coexistence of *cfr* and other resistance genes (*tet*(M), *bla*~TEM-1~*, floR, qnrS1*) on the same plasmid not only confers resistance to multiple agents, but also may allow for co-selection of *cfr* under selective pressure imposed by other agents, thus facilitating the dissemination of *cfr*. To date, the complete DNA sequences of five *cfr*-carrying plasmids from *E. coli*, including IncA/C plasmid pSCEC2 ([@B40]), conjugative plasmid pFSEC-01 ([@B38]), IncX4 plasmid pSD11 ([@B26]), and the two similar plasmids pGXEC6 and pGXEC3, have been reported ([@B39]). Our findings not only expand the range of plasmids that capture and spread *cfr*, but also emphasize the importance of IncFII plasmids, which have been reported to be involved in importance in the spread of many resistance genes, such as *floR*, *bla*~CTX-M~, *rmtB*, *oqxAB* ([@B35]), *bla*~CMY\ -2~, and *bla*~KPC~ ([@B8]), and *bla*~NDM~ ([@B11]).

Conclusion
==========

This is the first study to demonstrate the presence of *cfr* among *Staphylococcus* spp. and *E. coli* isolates on the same farm and the first report of the complete sequence of a novel F43:A-:B- plasmid carrying *cfr*. The extensive use of florfenicol as a preventative and treatment agent in swine farms in China most likely promotes and facilitates the spread of *cfr* across species and genus boundaries, mainly via horizontal transfer mediated by mobile elements including plasmids and insertion sequences such as IS*26* and IS*256*. Thus, rational use of florfenicol and alternating antibiotic therapy are required in order to reduce *cfr* dissemination, which constitutes a potential public health risk.
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